| Identification | Back Directory | [Name]
L-Cysteine, L-cysteinylglycyl-L-asparaginyl-L-lysyl-L-arginyl-L-threonyl-L-arginylglycyl-, cyclic (1→9)-disulfide | [CAS]
454487-07-1 | [Synonyms]
L-Cysteine, L-cysteinylglycyl-L-asparaginyl-L-lysyl-L-arginyl-L-threonyl-L-arginylglycyl-, cyclic (1→9)-disulfide | [Molecular Formula]
C36H65N17O12S2 | [MOL File]
454487-07-1.mol | [Molecular Weight]
992.14 |
| Chemical Properties | Back Directory | [density ]
1.65±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
2.95±0.70(Predicted) | [color ]
White to off-white | [Sequence]
Cys-Gly-Asn-Lys-Arg-Thr-Arg-Gly-Cys (Disulfide bridge: Cys1-Cys9) |
| Hazard Information | Back Directory | [Uses]
LyP-1 is a cyclic 9‐amino‐acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells[1]. | [in vivo]
LyP-1 (8?weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated group. In addition, a higher apoptotic rate in macrophages released from hypoxic plaques is observed after the treatment of LyP-1when compared to control peptide[1].The LyP-1 peptide is labeled with a near-infrared fluorophore (Cy5.5) for optical imaging.At days 3, 7, 14 and 21 after inoculation with 4T1 cells, tumor-bearing BALB/C mice is injected Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of the upper extremities of the tumor-bearing mice. The fluorescence intensities were 0.024, 0.038, 0.048 and 0.106×106?photon/cm2/sec respectively at days 3, 7, 14 and 21 after tumor cell inoculation, which are 1.02, 1.63, 2.04, and 4.52-fold higher than in the contralateral LNs. Cy5.5-LyP-1 staining in LNs co-localized with LYVE-1, suggesting lymphatics-specific binding of LyP-1 peptide[1]. | [References]
[1] Fan Zhang, et al.Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids. 2012 Jun;42(6):2343-51. DOI:10.1007/s00726-011-0976-1
[2] Ningning Song, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019 Dec;26(1):363-375. DOI:10.1080/10717544.2019.1587047 |
|
|